Literature DB >> 11522326

Selective D3 receptor agonist effects of (+)-PD 128907 on dialysate dopamine at low doses.

A Zapata1, J M Witkin, T S Shippenberg.   

Abstract

An involvement of the D3 dopamine receptor in the modulation of extracellular dopamine concentrations is suggested by pharmacological studies. However, recent studies using D3 receptor knock out mice indicated that several functions previously attributed to the D3 receptor are mediated by other receptor types. In the present study, we used the no-net flux microdialysis technique to characterize: (i) basal dopamine dynamics in the ventral striatum of D3 knock out and wild type mice and (ii) the effects of the putative D3-receptor selective agonist (+)-PD 128907. Neither the extracellular dopamine concentration nor the in vivo extraction fraction, an indirect measure of basal dopamine uptake, differed between D3 knock out and wild type mice. Moreover, no differences in potassium (60 mM) or cocaine (5 or 20 mg/kg i.p.) evoked dopamine concentrations were detected between the two genotypes. However, intra-striatal or systemic administration of doses of (+)-PD 128907 that failed to modify dopamine concentrations in knock out mice significantly decreased dialysate dopamine concentrations in the wild type. Comparison of the concentration-response curve for (+)-PD 128907 revealed IC(25) values of 61 and 1327 nM in wild type and knock out mice, respectively, after intra-striatal infusions. Similar differences were obtained after systemic administration of the D3 preferring agonist (IC(25) 0.05 and 0.44 mg/kg i.p. in wild type and knock out mice, respectively). We conclude that the activation of the D3 receptor decreases extracellular dopamine levels and that, at sufficiently low doses, the effects of (+)-PD 128907 on extracellular dopamine are selectively mediated by the D3 receptor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11522326     DOI: 10.1016/s0028-3908(01)00069-7

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  19 in total

1.  Relative expression of D3 dopamine receptor and alternative splice variant D3nf mRNA in high and low responders to novelty.

Authors:  Laurel M Pritchard; Aaron D Logue; Benjamin C Taylor; Rebecca Ahlbrand; Jeffrey A Welge; Yang Tang; Frank R Sharp; Neil M Richtand
Journal:  Brain Res Bull       Date:  2006-07-13       Impact factor: 4.077

Review 2.  The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.

Authors:  Christian A Heidbreder; Eliot L Gardner; Zheng-Xiong Xi; Panayotis K Thanos; Manolo Mugnaini; Jim J Hagan; Charles R Ashby
Journal:  Brain Res Brain Res Rev       Date:  2005-07

3.  Examining the role of dopamine D2 and D3 receptors in Pavlovian conditioned approach behaviors.

Authors:  Kurt M Fraser; Joshua L Haight; Eliot L Gardner; Shelly B Flagel
Journal:  Behav Brain Res       Date:  2016-02-22       Impact factor: 3.332

4.  C57BL/6J mice exhibit reduced dopamine D3 receptor-mediated locomotor-inhibitory function relative to DBA/2J mice.

Authors:  R K McNamara; B Levant; B Taylor; R Ahlbrand; Y Liu; J R Sullivan; K Stanford; N M Richtand
Journal:  Neuroscience       Date:  2006-08-28       Impact factor: 3.590

5.  A functional fast scan cyclic voltammetry assay to characterize dopamine D2 and D3 autoreceptors in the mouse striatum.

Authors:  Francis K Maina; Tiffany A Mathews
Journal:  ACS Chem Neurosci       Date:  2010-03-12       Impact factor: 4.418

6.  Dose-response analysis of locomotor activity and stereotypy in dopamine D3 receptor mutant mice following acute amphetamine.

Authors:  Robert K McNamara; Aaron Logue; Kevin Stanford; Ming Xu; Jianhua Zhang; Neil M Richtand
Journal:  Synapse       Date:  2006-10       Impact factor: 2.562

7.  Regulation of striatal dopamine release by presynaptic auto- and heteroreceptors.

Authors:  Hui Zhang; David Sulzer
Journal:  Basal Ganglia       Date:  2012-03-01

8.  Protein kinase Cβ is a modulator of the dopamine D2 autoreceptor-activated trafficking of the dopamine transporter.

Authors:  Rong Chen; Conor P Daining; Haiguo Sun; Rheaclare Fraser; Stephanie L Stokes; Michael Leitges; Margaret E Gnegy
Journal:  J Neurochem       Date:  2013-03-18       Impact factor: 5.372

9.  Dopamine D3 receptor ligands modulate the acquisition of morphine-conditioned place preference.

Authors:  Henriette Francès; Maria Smirnova; Ludovic Leriche; Pierre Sokoloff
Journal:  Psychopharmacology (Berl)       Date:  2004-04-17       Impact factor: 4.530

Review 10.  Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia.

Authors:  Gerhard Gross; Karsten Wicke; Karla U Drescher
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-11-06       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.